To address the molecular mechanism underlying the growth inhibition of the GIST‐T1 and GIST882 cell line by nintedanib in the presence of 20 ng·mL−1 FGF2, we tested the activated states of downstream mediators of the KIT and FGF signalling pathways (Fig. 4B). Here, KIT is linked to gastrointestinal stromal tumor.